Fuelled by sweeping regulatory reforms and a massive ageing population, China is a key market for most big biopharma companies, and Amgen is no exception.
The US biotech has just agreed a $2.7 billion deal with BeiGene that will give it a rapid route to rolling out its cancer drugs in China – both approved and in the development pipeline – as it tries to capture a bigger slice of a market expected to approach a value of $145-$175 billion by 2022.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,